ArticleBMC infectious diseases2026
Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn South Korea, the National Tuberculosis Expert Review Committee (NTBERC) has authorized the use of bedaquiline and delamanid in patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB) since September 1, 2016. We aimed to evaluate the treatment outcomes in patients who used these drugs under NTBERC approval prior to the introduction of short-course all-oral regimens.
methodsThis nationwide cohort study included patients with pulmonary MDR/RR-TB whose NTBERC-approved treatment included bedaquiline and/or delamanid and was initiated between September 1, 2016, and December 31, 2022. Treatment outcomes were categorized according to 2013 WHO definitions, and the treatment success rate was defined as the proportion of patients in the "cured" and "treatment completed" categories.
resultsDuring the study period, 2,078 patients applied for NTBERC approval, and 1,985 (95.5%) were approved. Among 1,546 patients included patients (median age 54.0 years; 69.0% male), 63.3% had FQ-susceptible TB and 28.5% had FQ-resistant TB; FQ data were unavailable in 8.2%. The median total treatment duration was 19.3 months and was shorter in the FQ-susceptible group than in the FQ-resistant group (19.1 vs. 20.7 months, p < 0.0001). The median duration of bedaquiline and delamanid use was 5.6 months. Patients received a median of 5.0 drugs, and the number of drugs was lower in the FQ-susceptible group than in the FQ-resistant group (5.0 vs. 6.0, p < 0.0001). The overall treatment success rate was 80.0%, with no significant difference between FQ-susceptible and FQ-resistant groups (81.5% vs. 80.3%, p = 0.58). Younger age (<60 years) and higher BMI (≥18.5 kg/m
conclusionsUnder South Korea's nationwide approval process, longer individualized regimens containing bedaquiline and/or delamanid achieved acceptable treatment success rate in patients with MDR/RR-TB, including patients with FQ resistance. CLINICAL TRIAL NUMBER: Not applicable.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.